A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease
- EligibilityCriteria: Inclusion Criteria:  Voluntary and signed informed consent, good compliance; Age 18-70 years old; Karnofsky Performance Scale (KPS) ≥60 points; Life expectancy ≥ 6months. Received allogeneic hematopoietic stem cell transplantation; Diagnosis of moderate-to-severe chronic graft-versus-host disease (cGVHD) Received systemic therapies for cGVHD; Stable dose of glucocorticoids, other immunosuppressant therapy received within 2 weeks prior to screening; Absolute Neutrophil Count (ANC) ≥ 1.0×10 9/L ；platelet count (PLT) ≥30×10 9 /L; Hemoglobin ≥80g/L; There were no obvious abnormalities in liver and kidney function and coagulation function; Men and women of childbearing age agree to use contraceptive measures during the study period and within 6 months after the end of the study  Exclusion Criteria:  Currently present or occured other malignancies within 3 years prior to first administration; Known or suspected active acute graft versus host disease (aGVHD); Presence of infection requiring treatment within 7 days prior to randomization; Failed allogeneic hematopoietic stem cell transplantation within 6 months or 2 prior allogeneic hematopoietic stem cell transplants; Use of Janus-activated kinase (JAK) inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, or other, chemotherapeutic agents within 2 weeks prior to randomization; Has a variety of factors that affect oral medications (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc; Those who have a history of psychotropic drug abuse and cannot be abstained from or have a mental disorder; Have any severe or uncontrolled serious illness, including but not limited to uncontrolled hypertension, heart disease, hepatitis and epilepsy that require treatment; Have any severe or uncontrolled serious illness, including but not limited to，uncontrolled hypertension heart disease, hepatitis and epilepsy that require treatment; Those who are allergic to the study drug or its components; Participation in other clinical trials or major surgery within 4 weeks prior to the first dose; Subjects judged by the investigator to be unsuitable for enrollment; - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult